Corbus Pharmaceuticals will present at the 2026 J.P. Morgan Healthcare Conference on January 15, 2026.
Quiver AI Summary
Corbus Pharmaceuticals Holdings Inc. announced that CEO Dr. Yuval Cohen will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. The presentation is scheduled for January 15 at 8:15 a.m. PST and will be followed by one-on-one investor meetings. Corbus, a clinical-stage company headquartered in Norwood, Massachusetts, focuses on oncology and obesity, with a pipeline that includes innovative therapies such as CRB-701, CRB-601, and CRB-913. The company's mission is to combat serious illnesses through novel scientific approaches targeting well-established biological pathways. For more details, the company encourages visiting their website and following them on social media.
Potential Positives
- Corbus Pharmaceuticals will present at the prestigious 2026 Annual J.P. Morgan Healthcare Conference, indicating increasing visibility and interest from the investment community.
- The company's CEO, Yuval Cohen, Ph.D., will deliver a corporate overview, showcasing the leadership's commitment to transparency and communication with investors.
- Corbus has a diversified pipeline, including innovative products targeting cancer and obesity, which positions the company well for potential growth and market impact.
- The press release highlights a focus on serious health issues, which could appeal to investors looking for socially responsible opportunities in the biotech sector.
Potential Negatives
- Company has not disclosed any new data or updates regarding the progress of its clinical-stage drugs, which may indicate a lack of significant advancement in its pipeline.
- Absence of specific information about upcoming presentations or milestones may raise concerns about the company's transparency and engagement with investors.
- Focus on a corporate overview presentation suggests a potential lack of recent breakthroughs or developments that might otherwise warrant a more detailed announcement.
FAQ
What is Corbus Pharmaceuticals focused on?
Corbus Pharmaceuticals focuses on oncology and obesity with innovative scientific approaches to treat serious illnesses.
When will Corbus present at the J.P. Morgan Healthcare Conference?
Corbus will present on January 15, 2026, at 8:15 a.m. PST/11:15 a.m. EST.
Where is the 2026 J.P. Morgan Healthcare Conference held?
The conference will be held in San Francisco, CA, from January 12-15, 2026.
What are the key products in Corbus' pipeline?
Corbus’ pipeline includes CRB-701, CRB-601, and CRB-913, targeting cancer and obesity treatments.
How can I connect with Corbus Pharmaceuticals online?
You can connect with Corbus on X, LinkedIn, and Facebook or visit their website at corbuspharma.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRBP Insider Trading Activity
$CRBP insiders have traded $CRBP stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $CRBP stock by insiders over the last 6 months:
- YUVAL COHEN (Chief Executive Officer) has made 0 purchases and 2 sales selling 27,633 shares for an estimated $471,203.
- SEAN F. MORAN (Chief Financial Officer) sold 12,981 shares for an estimated $220,936
- ANNE ALTMEYER sold 1,060 shares for an estimated $21,730
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRBP Hedge Fund Activity
We have seen 31 institutional investors add shares of $CRBP stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PROSIGHT MANAGEMENT, LP removed 236,493 shares (-40.8%) from their portfolio in Q3 2025, for an estimated $2,991,636
- BLACKROCK, INC. removed 125,511 shares (-35.6%) from their portfolio in Q3 2025, for an estimated $1,587,714
- ABERDEEN GROUP PLC added 116,005 shares (+160.6%) to their portfolio in Q3 2025, for an estimated $1,467,463
- ASSENAGON ASSET MANAGEMENT S.A. added 85,347 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,079,639
- MARSHALL WACE, LLP added 82,638 shares (+415.9%) to their portfolio in Q3 2025, for an estimated $1,045,370
- AMERIPRISE FINANCIAL INC added 69,625 shares (+inf%) to their portfolio in Q3 2025, for an estimated $880,756
- ACADIAN ASSET MANAGEMENT LLC removed 68,452 shares (-45.0%) from their portfolio in Q3 2025, for an estimated $865,917
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRBP Analyst Ratings
Wall Street analysts have issued reports on $CRBP in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 11/13/2025
- Wedbush issued a "Outperform" rating on 10/20/2025
To track analyst ratings and price targets for $CRBP, check out Quiver Quantitative's $CRBP forecast page.
$CRBP Price Targets
Multiple analysts have issued price targets for $CRBP recently. We have seen 4 analysts offer price targets for $CRBP in the last 6 months, with a median target of $46.5.
Here are some recent targets:
- Brian Abrahams from RBC Capital set a target price of $53.0 on 11/13/2025
- Andres Y. Maldonado from HC Wainwright & Co. set a target price of $40.0 on 10/20/2025
- Robert Driscoll from Wedbush set a target price of $38.0 on 10/20/2025
- Jeff Jones from Oppenheimer set a target price of $53.0 on 08/06/2025
Full Release
NORWOOD, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview at the 2026 Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026, in San Francisco, CA.
44
th
Annual J.P. Morgan Healthcare Conference
Format: Presentation and one-on-one investor meetings
Date: January 15, 2026
Presentation Time 8:15 a.m. PST/11:15am EST
Webcast Link:
Click Here
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a clinical stage oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload; CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells; and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit
corbuspharma.com
. Connect with us on
X
,
LinkedIn
and
Facebook
.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
[email protected]
Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
